Mashala will cost 62mill and the funding will be shown in the presentation on Tues. 300 mill shares to soph investore 200 mill - SPP convertible notes - $25 mill
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%